Brazilian Academy of Rhinology position paper on topical intranasal therapy  by de Mello Júnior, João Ferreira et al.
391
Brazilian Journal of otorhinolaryngology 79 (3) May/June 2013
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Brazilian Academy of Rhinology position paper on topical 
intranasal therapy
Abstract
João Ferreira de Mello Júnior1, Olavo de Godoy Mion2, Nilvano Alves de Andrade3, 
Wilma Terezinha Anselmo-Lima4, Aldo Eden Cassol Stamm5, Washingthon Luiz de Cerqueira Almeida3, 
Pedro Oliveira Cavalcante Filho6, Jair de Carvalho e Castro7, Francini Grecco de Melo Padua8, 
Fabrizio Ricci Romano9, Rodrigo de Paulo Santos3, Renato Roitmann10, Richard Louis Voegels1, 
Roberto Campos Meirelles11, Leonardo Conrado Barbosa Sá12, Moacyr Tabasnik Moacyr13, 
Marco Cesar Jorge dos Santos14, Roberto Eustáquio Santos Guimarães15
1 Senior Associate Professor - Medical School of the University of São Paulo (FMUSP).
2 Professor/Collaborator at the Otorhinolaryngology Program - University of São Paulo.
3 PhD in Otorhinolaryngology - Medical School of the University of São Paulo.
4 Associate professor - Medical School of Ribeirão Preto - University of São Paulo.
5 MSc in Otorhinolaryngology and PhD in Medicine - Federal University of São Paulo.
6 Professor/Coordinator of the Otorhinolaryngology Medical Residency Program - Federal University of Rio Grande do Norte.
7 PhD in Otorhinolaryngology - Federal University of São Paulo. Head of the Otorhinolaryngology Department - Santa Casa da Misericórdia - Rio de Janeiro.
8 PhD in Sciences - FMUSP, Collaborator Physician - Pediatric Otorhinolaryngology Program - Federal University of São Paulo.
9 PhD in Sciences - Medical School - University of São Paulo (FMUSP).
10 Associate Professor of Otorhinolaryngology - Medical School of the Lutheran University in Brazil. Associate Scientific Staff - Department of Otolaryngology Mount Sinai Hospital 
Toronto Ontario Canada.
11 Senior Associate Professor - State University of Rio de Janeiro.
12 MSc in Otorhinolaryngology - Federal University of Rio de Janeiro. Professor/Collaborator - Otorhinolaryngology Program - School of Medical Sciences - State University of 
Rio de Janeiro.
13 Head of the Otorhinolaryngology Service - Policlínica de Botafogo - Rio de Janeiro.
14 MD. Otorhinolaryngologist.
15 Associate Professor - Medical School of the Federal University of Minas Gerais. Senior Associate Professor - University of São Paulo/Ribeirão Preto.
Send correspondence to: João Ferreira de Mello Jr. Rua Dr. Eneas de Carvalho Aguiar, nº 255, 6º andar. São Paulo - SP. Brazil. CEP: 05403-000.
Paper submitted to the BJORL-SGP (Publishing Management System - Brazilian Journal of Otorhinolaryngology) on November 30, 2011;
and accepted on October 7, 2012. cod. 8928.
This documents aims at educating those who treat sinonasal diseases - both general practitioners 
and specialists - about topical nasal treatments. By means of scientific evidence reviews, the Brazilian 
Academy of Rhinology provides its practical and updated guidelines on the most utilized topical 
nasal medication, except for the drugs that have topical antibiotics in their formulas.
REVIEW ARTICLE
Braz J Otorhinolaryngol.
2013;79(3):391-400. BJORL
Keywords:
medication systems;
nasal cavity;
nose;
therapeutics.
.org
DOI: 10.5935/1808-8694.20130067
392
Brazilian Journal of otorhinolaryngology 79 (3) May/June 2013
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
INTRODUCTION
Inflammatory diseases of the nose and paranasal 
sinuses are among the most prevalent conditions to affect 
the general population. Diseases such as allergic and 
non-allergic rhinitis, acute and chronic rhinosinusitis with 
and without nasal polyps, cause significant decrease in 
the quality of life of the affected patients, and adversely 
affect one’s ability to perform activities connected to work, 
leisure, and socialization. These patients require specific 
specialized care.
Nasal topical medications are extremely important 
in the care of patients with inflammatory diseases of the 
nose and paranasal sinuses and upper airway infections. 
Although some drug classes have been used for decades, 
new medications have been made available to patients.
Given the prevalence of these diseases, significant 
direct and indirect expenditures are associated with tre-
atment, particularly when long term therapies are consi-
dered. The costs associated with treatment should not be 
neglected. Patients, their families, the public health care 
system and society may experience significant savings as 
a result of the judicious use of medication.
This paper aims to provide clarification to specialist 
physicians and general practitioners on the treatment of 
nose and sinus diseases with topical nasal medication. The 
Brazilian Academy of Rhinology reviewed the scientific 
evidence available to offer a practical updated overview 
on the most commonly used non-antibiotic topical nasal 
medications.
Topical intranasal steroids
Intranasal steroids have been effectively used to 
treat allergic rhinitis, rhinosinusitis, and nasal polyps1, in 
addition to a wide array of non-allergic rhinitis, such as 
idiopathic, vasomotor, and gestational rhinitis2.
Increased knowledge on the pharmacology of 
glucocorticoid and steroid receptors has enabled the 
development of molecules designed to potently reach 
specific localized activity with minimum risk of systemic 
side effects3.
The introduction of topical glucocorticoids and 
steroids (GCS) has significantly enhanced the treatment of 
upper and lower airway diseases. Their clinical efficacy 
may depend partly on the ability to reduce eosinophilic 
function and infiltration by inhibiting the activation and 
viability of eosinophils4-6. They may also act to reduce the 
release of chemotactic enzymes on the nasal mucosa and 
polyp epithelial cells7. The potency of these drugs is lesser 
in nasal polyps than in the nasal mucosa, thus suggesting 
that nose polyps may present induced inflammatory re-
sistance to therapy with steroids8.
The biological effect of GCS is mediated by the in-
tracellular activation of glucocorticoid receptors9 expressed 
in most tissues and cells. Two different GCS receptor 
isoforms have been identified in humans, alpha (GRa) 
and beta (GRb), both originated in the same gene and 
divided after the primary transcription of the glucocorticoid 
receptor10. As GRa binds to a hormone, it increases pro-
-inflammatory genetic transcription and produces most of 
the anti-inflammatory effect seen in GCS through protein 
interactions between glucoreceptors and transcription 
factors such as AP-1 and NF-KB. GRb does not bind to 
steroids, but may interfere with GRa function. A number 
of mechanisms are probably involved in resistance to 
the anti-inflammatory effect provided by GCS, including 
exaggerated expression of GRb or reduced expression of 
GRa. Increases in GRb expression have been seen in pa-
tients with nasal polyps11,12, while downregulation of GRa 
levels has been reported after treatment with GCS13,14 as 
one of the possible explanations for secondary resistance 
to GCS15. Theoretically, the anti-inflammatory effects of 
GCS may be seen in allergic and non-allergic rhinosi-
nusitis, for instance in cases of infectious rhinosinusitis; 
tissue eosinophilia is also found in patients with chronic 
or persistent rhinosinusitis16.
Each glucocorticoid and steroid has unique mole-
cular, pharmacokinetic, and pharmacodynamic properties, 
which lead to drugs with different modes of action. For 
example, furoate increases GCS potency and selectivity for 
the mineralocorticoid receptor17. Ciclesonide is an inactive 
drug converted to a pharmacologically active metabolite, 
des-isobutyryl-ciclesonide, by upper and lower airway es-
terases18. Ciclesonide and budesonide - the latter not a pro-
drug - also form fatty acid esters after topical administration 
on the nasal mucosa (budesonide oleate and budesonide 
palmitate), thus contributing to their intracellular retention 
in the nasal mucosa19. Pharmacological studies on potency 
using affinity as the only criterion yielded a classification 
for GCS. Mometasone furoate, fluticasone furoate, and 
fluticasone propionate were ranked as the most potent 
intranasal glucocorticoids and steroids20. The side chains 
in furoate and propionate allow these esters to be highly 
lipophilic, a quality that may facilitate their absorption 
by the nasal mucosa and further progression through the 
cell membrane phospholipase. These compounds do not 
present significant systemic absorption, with values under 
1%, together with ciclesonide21.
Studies have shown higher rates of systemic ab-
sorption in older GCS, such as beclomethasone dipro-
pionate, triamcinolone acetonide, and budesonide, with 
bioavailability ranging between 34% and 49%. However, 
the one-year studies carried out on mometasone, flutica-
sone propionate, and budesonide to assess the potential 
systemic side effects in children did not reveal adverse 
effects on the hypothalamic-pituitary-adrenal axis or upon 
its growth. In theory, medications with lower levels of bio-
availability should be given preference for being closer to 
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the pharmacokinetic and pharmacodynamic traits desired 
in an ideal course of therapy. However, studies have failed 
to confirm this assumption22-26. These drugs are very useful 
in managing symptoms and, therefore, can be administered 
in a chronic regimen (Table 1).
Topical intranasal glucocorticoids and steroids 
are effective against seasonal and perennial allergic rhi-
nitis, non-allergic rhinitis, and episodic rhinitis, as they 
effectively manage all rhinitis symptoms, including nasal 
congestion.
Onset of action is usually slower than oral and 
intranasal antihistamines, occurring within 12 hours in 
most patients or in three to four hours in some subjects 
after provocation tests. Full effect takes longer to occur.
When compared to other drug classes, topical 
GCS are more effective than the combination of oral 
antihistamines and antileukotriene agents for seasonal or 
perennial allergic rhinitis. Their efficacy is comparable 
to that of oral antihistamines for ocular symptoms of 
allergic rhinitis. Fluticasone furoate has been the most 
frequently studied drug for ocular symptoms of patients 
with rhinoconjunctivitis, and was found to be significan-
tly more effective than placebo and just as effective as 
antihistamines27,28.
No systemic side effects have been observed in 
adults, nor have adverse impact on the growth of children 
with perennial allergic rhinitis been described, when the 
drug is administered in the recommended dosages. Local 
side effects are minimal, but nasal irritation and bleeding 
may occur. Cases of septal perforation have been repor-
ted, although rarely. Drug effect in children and pregnant 
women is very similar to that observed in adult subjects. 
However, given the potential unexpected consequences, 
GCS must be judiciously prescribed and administered to 
these two populations.
Studies on the use of topical intranasal GCS in 
children have not described adverse effects or significant 
levels of systemic absorption. In pregnant women there is 
always the concern with the embryo and the association 
with cleft palate, but up to now no teratogenic effects 
have been reported, despite the few studies done on the 
matter. Therefore, the risks and benefits provided by these 
medications must be considered when they are prescribed 
to pregnant individuals. The only intranasal GCS assigned 
category B by the Food and Drug Administration for use 
in pregnant subjects is budesonide29. Additionally, the re-
commendation states that it be used in the lowest dosage 
possible and for as short as possible. When glaucoma is 
considered, the literature features reports associating in-
traocular pressure worsening and use of intranasal GCS. 
However, other studies have not correlated onset of glau-
coma and chronic use of mometasone and ciclesonide. 
Patients with glaucoma prescribed topical intranasal GCS 
should be followed by an ophthalmologist until more 
knowledge on the topic has been gathered.
Clinical trials indicate that there is no difference in 
efficacy between intranasal GCS medications, but most 
have compared them to placebo. Few studies have made 
head-to-head comparisons between GCS medications to 
assess efficacy.
Treatment of rhinosinusitis with topical GCS
Many are the indications to use topical intranasal 
GCS in rhinosinusitis, ranging from acute to chronic di-
sease (Table 2).
Considering rhinosinusitis, many studies have 
looked into single-drug therapy regimens with GCS and 
GCS as adjuvant drugs. Authors have studied budesoni-
de30-38, mometasone39,40, fluticasone furoate, fluticasone 
propionate41-47, and beclomethasone dipropionate48-52 and 
reported improved symptom scores in regimens with 
antibiotics and significant differences when other criteria 
were analyzed, such as x-ray images and CT scans, or nasal 
peak flows and acoustic rhinometry or rhinomanometry. 
One study reported significant reductions in symptoms of 
acute rhinosinusitis comparing placebo and antibiotics53.
Table 1. General characteristics of the formulations of intranasal steroids, age from which they can be used in allergic rhinitis, and 
corresponding dosages for children and adults.
Name Formulation Minimum age Dose per spray mcg*/nostril
Maximum 
dose/children 
mcg/day
Dose/adults 
mcg/day
Maximum dosa-
ge for rhinitis and 
nasal polyps** 
mcg/day
Triamcinolone acetonide Isotonic 4 years 55 110 220 220
Budesonide Isotonic 6 years 32, 50, 64, 100 100 200 400
Ciclesonide Hypotonic 6 years 50 100 200 400
Beclomethasone dipropionate Isotonic 6 years 50 100 200 400
Mometasone furoate Isotonic 2 years 50 100 200 400
Fluticasone propionate Isotonic 2 years 50 100 200 400
Fluticasone furoate Isotonic 4 years 27.5 52.5 105 210
* mcg micrograms. Source: Medication inserts, ** Standard dosages are not available for nose polyps at present; clinical trials usually use the 
medication’s maximum dosage3.
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Topical GCS medications have known effects upon 
nasal polyps and associated symptoms such as obstruction, 
secretion, and sneezing, although smell is affected to a 
lesser degree. High level evidence is available on polyp 
size reduction.
In regards to prevention, low level evidence is 
available on the prophylactic effects of nasal GCS upon 
recurrent acute rhinosinusitis.
Scientific knowledge on GCS, their effects on the 
glucocorticoid receptor and cell transcription processes 
has grown and improved our understanding of this drug 
class and its use in therapeutic settings.
Despite the significant amount of information avai-
lable, the clinical differences between each compound are 
still not clear. As a drug class, intranasal GCS medications 
have comparable levels of efficacy in the treatment of 
upper airway inflammatory diseases.
The commercially available GCS medications are 
close to reaching the ideal pharmacokinetic and pharma-
codynamic properties of this drug class in topical nasal 
applications, namely:
1. High affinity to the receptor, potency, and 
specificity to the nasal mucosa;
2. Low systemic bioavailability;
3. High rate of hepatic clearance and fast systemic 
elimination;
4. Single daily dosage.
However, studies are being carried out to find even 
better drugs considering the criteria above.
Topical nasal antihistamines
Intranasal antihistamines may be considered 
as the first-line treatment for allergic and non-allergic 
non-infectious rhinitis54,55, and are as effective or better 
than second generation oral antihistamines in the treat-
ment of seasonal allergic rhinitis56,57, although they are 
usually less effective than intranasal GCS in the treatment 
of allergic rhinitis58. However, they have been associated 
with clinically significant effect upon nasal congestion59.
The only intranasal antihistamine currently available 
in our practice is azelastine, a drug characterized by good 
efficacy and quick onset of action60. Azelastine has been 
approved for the treatment of seasonal and perennial al-
lergic rhinitis, and showed effect upon nasal congestion, 
rhinorrhea, sneezing, and nasal itching. It was the first 
antihistamine associated with significant clinical reduc-
tion of nasal congestion61, in addition to being the first 
effectively used in cases of non-allergic rhinitis. However, 
given their systemic absorption, intranasal antihistamines 
have been associated with sedation and may inhibit the 
histamine reaction in skin tests1.
Several studies have reported that their efficacy 
against seasonal rhinitis is greater than or equal to that 
of second generation oral antihistamines59. A systematic 
review encompassing nine randomized controlled trials 
comparing intranasal antihistamines and intranasal GCS62 
concluded that intranasal GCS medications are more 
effective in managing the nasal symptoms of perennial 
and seasonal rhinitis. Significant benefits may be yielded 
when intranasal antihistamines and intranasal GCS are 
combined55, although such combination is not commonly 
utilized.
Azelastine is formulated as an aqueous solution and 
administered in the form of a nasal spray with a dosage of 
1 mg/ml. It is recommended that each nostril be sprayed 
twice a day in patients above 12 years of age. Half the 
dosage is recommended for children aged five and older. 
Onset of action takes about 15 minutes for significant cli-
nical improvement, a fact that places azelastine as a drug 
to be used in the early stages of allergy bouts1.
Clinical trials on azelastine reported that approxi-
mately 19% of the patients complained of bitter taste and 
11% reported sleepiness1.
Intranasal antihistamines are absorbed by the 
gastrointestinal tract, and azelastine may thus suppress 
reactions in the skin test for up to 48 hours63.
Intranasal disodium cromoglycate
Intranasal disodium cromoglycate has been effective 
for some patients in the prevention and treatment of aller-
gic rhinitis, and has not been associated with side effects. It 
prevents immediate allergic reactions more than it provides 
symptom relief after the reaction has begun64. It is also 
used in maintenance allergic rhinitis treatment, with onset 
of action ranging from four to seven days. Full action may 
take weeks to occur65. In episodic rhinitis, use immediately 
before exposure to antigens protects subjects for four to 
eight hours against immediate allergic response66.
It acts by inhibiting the degranulation of mast cells, 
consequently preventing the release of immediate allergic 
response and allergic inflammation mediators. This drug 
has a unique mode of action and is known for not being 
a bronchodilator, antihistamine, or direct anti-inflammatory 
agent67.
The 4% spray solution is indicated for the treatment 
of seasonal and perennial allergic rhinitis. When used in 
the treatment of symptoms of seasonal allergic rhinitis, 
cromoglycate must be started early on in the beginning 
Table 2. Potential indications for topical nasal glucocorticoids 
and steroids in cases of rhinosinusitis3.
Acute rhinosinusitis
Chronic rhinosinusitis without nasal polyps
Chronic rhinosinusitis with nasal polyps
Postoperative care of chronic rhinosinusitis patients to prevent 
nasal polyp recurrence
Prophylactic care of patients with recurrent acute rhinosinusitis
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of the allergy season. Effect is usually noted four to seven 
days after the start of treatment. However, more seve-
re or perennial cases require two weeks or more until 
maximum effect sets in. Very symptomatic patients may 
need combined therapy with antihistamines and/or nasal 
decongestants during the first days of treatment, given 
the need of proper contact with the nasal mucosa for the 
drug to be effective1. Treatment must be continued by 
offering the patient a maintenance dosage that is effective 
for the remainder of the season or period of exposure to 
the antigens.
Cromoglycate has been effectively used in the treat-
ment of episodic rhinitis when contact with or exposure to 
the allergen can be anticipated. In these cases, its onset of 
action appears to be faster. The protective effect provided 
by cromoglycate against antigen nasal provocation persists 
for four to eight hours after administration, thus enabling 
preventive care when exposure can be predicted, as in 
the case of veterinarians with allergies.
In controlled trials, cromoglycate was better than 
placebo. A double-blind randomized placebo-controlled 
trial with children aged between two and five years of 
age revealed cromoglycate provided relief from allergic 
rhinitis symptoms. However, cromoglycate was in gene-
ral less effective than intranasal GCS, and has not been 
properly studied in relation to leukotriene antagonists and 
antihistamines68-70.
Cromoglycate is a safe medication, Adverse effects 
are usually mild and local, and include sneezing and sensa-
tion of burning. No cases of crust of septal perforation have 
been described. There is no clinical evidence indicating 
patients could experience overdosages of cromoglycate.
Given its excellent safety profile and absence of 
significant interactions with other drugs, cromoglycate 
may be considered and prescribed to young children and 
pregnant women71,72, thus serving as a valuable alterna-
tive when other nasal sprays are contraindicated or not 
tolerated by the patient.
Proper patient selection is critical when cromogly-
cate is considered. Reviews have described the limited 
role cromoglycate has in the treatment and prevention 
of allergic rhinitis symptoms71. There is no evidence 
that cromoglycate may benefit patients with non-allergic 
non-infectious rhinitis (NARES) or nasal polyps72.
Nasal decongestants
Nasal congestion is one of the most troubling 
symptoms for patients with rhinitis73. The medications with 
the best effect on this symptom are nasal decongestants, 
sympathomimetic drugs that act directly on the capacitance 
vessels of the turbinates.
They are available in oral (pseudoephedrine and 
phenylephrine) and intranasal topical (phenylephrine, 
naphazoline, and oxymetazoline) formulations. Both can 
produce increased blood pressure, agitation, headaches, 
anxiety, insomnia, tremor, palpitations, dry mucosa, urina-
ry retention in patients with enlarged prostates, glaucoma 
worsening, and thyrotoxicosis2,74.
Topical vasoconstrictors usually start acting within 
around 10 minutes. However, when used for more than 
five or ten days, they may lead to the appearance of 
drug-induced rhinitis as a consequence of their rebound 
effect. The ARIA (Allergic Rhinitis and its Impact on Asthma) 
initiative does not recommend its use on children with 
allergic rhinitis, and states that adults should limit its use 
to a maximum of five days2.
These drugs must be judiciously used in patients 
taking monoamine oxidase inhibitors (MAOIs), antihyper-
tensive drugs, digitalis, and L-DOPA.
Inert cellulose powder
Inert cellulose powder has been used as a thickener 
in various liquid formulations of nasal application. Natural 
inert cellulose was recently approved for use in rhinitis 
patients in Brazil.
Cellulose powder is known to hamper bacterial 
growth, even though its exact mode of action in allergic 
rhinitis has not been fully explained. It is believed to form 
a gelatinous membrane on the epithelium when applied to 
the nasal mucosa. The gelatinous membrane has greater 
surface tension than mucus, and acts as a more effective 
barrier to antigen penetration, which cannot reach the 
effector cells. Thus, it would not affect symptoms, but the 
entire allergic process by impacting the development of 
the allergic inflammatory cascade75.
A study carried out on the effects of inert cellulose 
powder in allergic rhinitis by pollen showed that patients 
using micronized cellulose powder required significantly 
less salvage medication to manage nasal symptoms76.
Additionally, patients with allergic rhinitis by mites 
using cellulose powder had fewer nasal symptoms in nasal 
provocation tests for these antigens77.
As it is not a medication, the medical literature on 
inert cellulose powder is scarce and unclear about its mode 
of action, action on the mucociliary barrier, and dosage.
Saline solutions
The use of saline solutions in nasal hygiene has 
been recommended by specialists, but their effects may 
go beyond those of an adjuvant therapy1-3. Saline solu-
tion has been indicated for patients with allergic rhinitis, 
non-allergic rhinitis, acute and chronic rhinosinusitis, and 
even non-specific conditions such as postnasal drip1-3.
Our patients have been advised for years to use 
isotonic (0.9%) sodium chloride solutions. In the 1990’s, 
hypertonic (2% or 3%) sodium chloride solutions were 
introduced. They were initially used in nose surgery posto-
perative care to ease the removal of crusts. More recently, 
396
Brazilian Journal of otorhinolaryngology 79 (3) May/June 2013
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
the medical literature has reported that these solutions are 
also useful in controlling nasal symptoms of patients with 
other clinical conditions such as rhinitis.
Nasal washing with isotonic saline solution is an 
easy, well tolerated and beneficial procedure with practi-
cally no relevant adverse side effects78. The most common 
complaint associated with it is sensation of local irritation, 
in some cases related to the concentration or conservatives 
added to the solution.
Benzalkonium chloride is a surfactant belonging to 
the quaternary ammonium group used to prevent contami-
nation by bacteria and preserve pharmacological activity of 
topical nasal, ocular, auricular, and cutaneous medication. 
Its hydrophobic and cationic groups act to increase the 
permeability of bacterial cell membrane, thus conferring 
it bactericidal properties79,80.
In vitro studies have shown that the deleterious 
effects of benzalkonium chloride on ciliary beat rates de-
creases with drops in pH. This finding has been observed 
in pH reductions to 7.4 and even 6.0. As the nasal mucus 
pH is situated between 5.5 and 6.0, it is reasonable to assu-
me that this fact could interfere with the direct correspon-
dence between in vitro results and physiological conditions 
of the nasal cavities. There is no concrete evidence to state 
that benzalkonium chloride hurts the human mucociliary 
barrier in vivo, but the substance has been accounted for 
the bitter taste of certain nasal preparations81,82.
Nasal washing with hypertonic solution (3%) is safe 
and carries minimal side effects. A few cases of local irri-
tation, itching, burning, otalgia, and sensation of pressure 
on the face have been described in the literature83.
The exact mode of action of nasal washing with 
saline solution is still being studied. Some possibilities 
have been considered, such as mechanical cleaning of 
the nose, dilution of nasal mucus, induction of rhinorrhea, 
and effects upon ciliary beat rate and ciliary clearance83.
The use of saline solution increases the movements 
of mucus toward the rhinopharynx by mechanical action. 
The justification for this hypothesis is based on patient 
reports of increased efficacy in forced washing cycles, such 
as in cases in which saline solution is gently injected into 
the nasal cavity with a syringe. Additionally, when forced 
washing is performed, crusts are softened and removed 
more easily. Thick secretion can also become less viscous 
and be more easily removed84.
In nasal diseases, various chemical inflammatory 
mediators are released and dissolved in mucus, acting 
directly and indirectly on the mucosa and inducing ede-
ma and ciliary beat alterations. Saline solution removes 
and/or dilutes these mediators, thus reducing local in-
flammation and, consequently, edema. A reduction on 
levels of histamine and leukotriene C
4
 has been observed 
in the nasal washes of patients using hypertonic saline 
solution85. Additionally, the use of hypertonic solution on 
the nasal mucosa may induce the release of substance P, 
an important neuropeptide that induces rhinorrhea in a 
dose-dependent fashion86.
Ciliary beating is a relevant defense mechanism 
of the respiratory tract, and reductions in it have been 
associated with respiratory diseases such as rhinitis, rhino-
sinusitis, asthma, and otitis media. In healthy individuals 
without nasal complaints, the saccharin test (in vivo) has 
shown that hypertonic saline solution (3%) significantly 
improves ciliary beating, an event not seen with isotonic 
saline solution87.
In vitro studies have shown that both isotonic and 
hypertonic solutions may affect ciliary beat rates. In vitro 
ciliated cells of the nasal mucosa treated with saline solu-
tions in different concentrations (0.06%; 0.12%; 0.9%; 3.0%; 
7.0%) only presented altered ciliary beating in hypertonic 
concentrations88. On the other hand, some authors have 
observed moderate negative impact on ciliary beating in 
cells treated with isotonic saline solution. When solutions 
in higher concentrations were used (7%; 14%), ciliary be-
ating ceased after five minutes, a finding reversible only 
in 7% saline solution89.
An in vitro study - thus in the absence of the pro-
tection offered by nasal mucus - on cultured human nasal 
epithelial cells compared the effects of hypotonic (0.3%), 
isotonic, and hypertonic (3.0%) saline solutions on gland 
secretion and cell morphology. The three solutions did not 
affect total mucin secretion. However, in the 0.3% and 3.0% 
concentrations the epithelium was injured, a condition not 
observed with isotonic saline solution90.
Another interesting point concerning nasal washing 
refers to the pH of the used solution. A double-blind rando-
mized trial found that buffered (pH = 8) and non-buffered 
hypertonic saline solutions significantly increased muco-
ciliary clearance, without significant differences between 
the two solutions91.
Tonicity of saline solutions was found to affect the 
absorption of topical medications. The bioavailability of 
calcitonin applied on the nose in hypotonic or hyperto-
nic saline solutions was four to five times greater than 
when an isotonic formulation was used92. Thus, the cell 
concentration of ciclesonide is higher when nasal topical 
ciclesonide is applied with hypotonic saline solution versus 
isotonic saline solution93.
Saline solutions can be applied in three different 
ways. The simplest involves the use of negative pressure, 
in which saline solution is poured on the palm of the hand 
and introduced in the nasal fossae by forced inhalation. 
Another method employs positive pressure to distribute 
the fluid in the nasal fossae, such as when syringes or 
eyedroppers are used. The last option is to use sprays, an 
easy-to-carry option for patient medication94. Each of the 
possibilities has its pros and cons, but patient compliance 
must be considered in any of them.
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CT scans done after nasal washing with saline 
solution and ionic contrast have shown greater penetration 
of the solution into the maxillary and ethmoid sinuses 
when positive pressure approaches were used than when 
sprays were employed94. Likewise, an analysis of airflow 
through the different areas of the nasal fossae showed that 
airflow was very limited in the paranasal sinuses, which 
are protected by the uncinate process and the middle 
nasal concha, thus explaining the reduced effectiveness 
of sprays in reaching these sites95.
It is worth mentioning that these approaches refer 
to the application of saline solution, and not nasal 
spray medication. For these, it is recommended that 
patients gently blow their noses before using the topical 
medication to facilitate penetration. The goal is that the 
medication makes it to the turbinates, and thus patients 
have to be instructed to direct the tip of the delivery 
device to the lateral wall of the nasal cavity21. In practical 
terms, patients are advised to apply the medication on 
the left nasal fossa with the right hand and vice-versa. 
As the patient applies pressure onto the device’s valve, 
it is recommended that he/she closes the contralateral 
nostril with a finger while air is gently inhaled during 
the application of the medication96.
Although nasal hygiene with saline solution is 
recommended by a number of consensus papers, the 
literature on the topic is limited. More clinical and labora-
tory trials are required. Nonetheless, some points must be 
observed, such as not using cold or hot solutions. Saline 
solution does not ease symptoms promptly, and patient 
compliance may become an issue. However, the qualities 
of saline solution (low cost, few adverse side effects, etc) 
fully justify its use.
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